Novartis Presents Positive Two-Year Data for Ianalumab in Sjögren's Disease at ACR 2026

Novartis Pharma AG announced long-term results from the NEPTUNUS extension study of ianalumab, showing continued improvements in systemic disease activity, physician- and patient-reported outcomes, and salivary flow in patients with Sjögren's disease. The data was presented at the American College of Rheumatology Convergence 2026.

Context

Sjögren's disease primarily affects the body's moisture-producing glands, leading to symptoms like dry mouth and eyes. Current treatment options are limited, making new therapies like ianalumab crucial. The NEPTUNUS extension study aims to evaluate the long-term efficacy and safety of this investigational drug.

Why it matters

The presentation of long-term data for ianalumab is significant as it indicates ongoing improvements in patients with Sjögren's disease, a chronic autoimmune condition. Effective treatments can enhance the quality of life for those affected. This data may influence treatment protocols and healthcare decisions for managing the disease.

Implications

If ianalumab receives approval, it could provide a new therapeutic option for patients with Sjögren's disease, potentially improving their daily lives. The pharmaceutical market may see increased competition in autoimmune treatments. Patients and healthcare providers will need to stay informed about the drug's availability and any new clinical guidelines.

What to watch

Following this presentation, healthcare providers may begin to incorporate ianalumab into treatment plans for Sjögren's disease. Observers should monitor any regulatory decisions regarding the drug's approval. Additionally, further studies may be announced to explore its effects in broader patient populations.